Tumor-microenvironment interactions studied by zonal transcriptional profiling of squamous cell lung carcinoma

Genes Chromosomes and Cancer

Volumn 52, Issue 3, 2013, Pages 250-264

  Wu, Hui ^a,f   Haag, Daniel ^a,f   Muley, Thomas ^b,c,f   Warth, Arne ^d,f   Zapatka, Marc ^a,f   Toedt, Grischa ^a,f   Pscherer, Armin ^a,f   Hahn, Meinhard ^a,f   Rieker, Ralf J ^d,e,f   Wachter, David L ^e,f   Meister, Michael ^b,c,f   Schnabel, Philipp ^d,f   Müller Decker, Karin ^a,f   Rogers, Michael A ^a,f   Hoffmann, Hans ^b,f   Lichter, Peter ^a,f  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Translational Lung Research Center (TLRC H)   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f BioRN Cluster Management GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; ICOSANOID; MESSENGER RNA; MICRORNA;

ADULT; AGED; ARACHIDONIC ACID METABOLISM; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; ICOSANOID METABOLISM; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LASER CAPTURE MICRODISSECTION; LUNG PARENCHYMA; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOCYTE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TUMOR MICROENVIRONMENT;

CARCINOMA, SQUAMOUS CELL; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; REPRODUCIBILITY OF RESULTS; TRANSCRIPTOME; TUMOR MICROENVIRONMENT;

EID: 84872379364     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22025     Document Type: Article

References (74)

1. Ahmadi M, Emery DC, Morgan DJ. 2008. Prevention of both direct and cross-priming of antitumor CD8(+) T-cell responses following overproduction of prostaglandin E-2 by tumor cells in vivo. Cancer Res 68: 7520-7529.
2. Alaa M, Suzuki M, Yoshino M, Tian L, Suzuki H, Nagato K, Fujiwara T, Wada H, Moriya Y, Hoshino H, Motohashi S, Yoshida S, Shibuya K, Hiroshima K, Nakatani Y, Abdrabou A, Elkholy M, Mahfouz T, Yoshino I. 2009. Prostaglandin E2 receptor 2 overexpression in squamous cell carcinoma of the lung correlates with P16(INK4A) methylation and an unfavorable prognosis. Int J Oncol 34: 805-812.
3. Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc'h N, Zeng G, Reckamp K, Dohadwala M, Sharma S, Dubinett SM. 2005. Prostaglandin E-2 induces FOXP3 gene expression and T regulatory cell function in human CD4(+) T cells. J Immunol 175: 1483-1490.
4. Benjamini Y, Hochberg Y. 2011. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc B 57: 289-300.
5. Berta J, Kenessey I, Dobos J, Tovari J, Klepetko W, Ankersmit HJ, Hegedus B, Renyi-Vamos F, Varga J, Lorincz Z, Paku S, Ostoros G, Rozsas A, Timar J, Dome B. 2010. Apelin expression in human non-small cell lung cancer role in angiogenesis and prognosis. J Thorac Oncol 5: 1120-1129.
6. Boelens MC, Van Den Berg A, Fehrmann RSN, Geerlings M, De Jong WK, Meerman GJT, Sietsma H, Timens W, Postma DS, Groen HJM. 2009. Current smoking-specific gene expression signature in normal bronchial epithelium is enhanced in squamous cell lung cancer. J Pathol 218: 182-191.
7. Brigl M, Brenner MB. 2004. CD1: Antigen presentation and T cell function. Annu Rev Immunol 22: 817-890.
8. Charles CJ. 2007. Putative role for apelin in pressure/volume homeostasis and cardiovascular disease. Cardiovasc Hematol Agents Med Chem 5: 1-10.
9. Chen CY, Zhang YQ, Zhang LD, Weakley SM, Yao QZ. 2011. Microrna-196: Critical roles and clinical applications in development and cancer. J Cell Mol Med 15: 14-23.
10. Du LQ, Pertsemlidis A. 2010. MicroRNAs and lung cancer: Tumors and 22-mers. Cancer Metastasis Rev 29: 109-122.
11. Edge SB. 2010. AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer Verlag.
12. Feng L, Xie Y, Zhang H, Wu YL. 2011. Down-regulation of NDRG2 gene expression in human colorectal cancer involves promoter methylation and microrna-650. Biochem Biophys Res Commun 406: 534-538.
13. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
14. Forster R, Davalos-Misslitz AC, Rot A. 2008. CCR7 and its ligands: Balancing immunity and tolerance. Nat Rev Immunol 8: 362-371.
15. Freier K, Bosch FX, Flechtenmacher C, Devens F, Benner A, Lichter P, Joos S, Hofele C. 2003. Distinct site-specific oncoprotein overexpression in head and neck squamous cell carcinoma: A tissue microarray analysis. Anticancer Res 23: 3971-3977.
16. Gray SG, Al Sarraf N, Baird AM, Cathcart MC, Mcgovern E, O'Byrne KJ. 2009. Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. Eur J Cancer 45: 3087-3097.
17. Gugger M, White R, Song S, Waser B, Cescato R, Riviere P, Reubi JC. 2008. GPR87 is an overexpressed G-protein coupled receptor in squamous cell carcinoma of the lung. Dis Markers 24: 41-50.
18. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T. 2005. A polycistronic microrna cluster, Mir-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65: 9628-9632.
19. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. 2005. A microrna polycistron as a potential human oncogene. Nature 435: 828-833.
20. Hillinger S, Yang SC, Batra RK, Strieter RM, Weder W, Dubinett SM, Sharma S. 2006. CCL19 reduces tumour burden in a model of advanced lung cancer. Brit J Cancer 94: 1029-1034.
21. Hoang CD, D'Cunha J, Tawfic SH, Gruessner AC, Kratzke RA, Maddaus MA. 2004. Expression profiling of non-small cell lung carcinoma identifies metastatic genotypes based on lymph node tumor burden. J Thorac Cardiovasc Surg 127: 1332-1342.
22. Holzinger I, Debaey A, Messer G, Kick G, Zwierzina H, Weiss EH. 1995. Cloning and genomic characterization of Lst1-A new gene in the human Tnf region. Immunogenetics 42: 315-322.
23. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H, Dubinett SM. 1998. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 58: 1208-1216.
24. Huang X, Le QT, Giaccia AJ. 2010. Mir-210-Micromanager of the hypoxia pathway. Trends Mol Med 16: 230-237.
25. Hughes D, Otani T, Yang P, Newman RA, Yantiss RK, Altorki NK, Port JL, Yan M, Markowitz SD, Mazumdar M, Tai HH, Subbaramaiah K, Dannenberg AJ. 2008. NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res 1: 241-249.
26. Joyce JA, Pollard JW. 2009. Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252.
27. Kalluri R, Weinberg RA. 2009. The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
28. Kan ZY, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng JB, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VEH, Yuan WL, Li L, Wang WR, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang ZM, Stokoe D, De Sauvage FJ, Faham M, Seshagiri S. 2010. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466: U869-U103.
29. Katz HR. 2007. Inhibition of pathologic inflammation by leukocyte Ig-like receptor B4 and related inhibitory receptors. Immunol Rev 217: 222-230.
30. Keith RL, Geraci MW, Nana-Sinkam SP, Breyer RM, Hudish TM, Meyer AM, Malkinson AM, Dwyer-Nield LD. 2006. Prostaglandin E-2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis. Anticancer Res 26: 2857-2861.
31. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi K, Imai K, Nakamura Y. 2003. Expression profiles of non-small cell lung cancers on Cdna microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22: 2192-205.
32. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, Dubinett SM. 2005. Prostaglandin E-2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 65: 6275-6281.
33. Landi MT, Zhao YD, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola FM, Tucker MA, Bertazzi PA, Pesatori AC, Caporaso NE, Mcshane LM, Wang E. 2010. Microrna expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 16: 430-441.
34. Liang Y. 2008. An expression meta-analysis of predicted microrna targets identifies a diagnostic signature for lung cancer. BMC Med Genomics 1: 61.
35. Liu M, Lang N, Qiu M, Xu F, Li Q, Tang Q, Chen J, Chen X, Zhang S, Liu Z, Zhou J, Zhu Y, Deng Y, Zheng Y, Bi F. 2011. Mir-137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells. Int J Cancer 128: 1269-1279.
36. Luo H, Zhang H, Zhang Z, Zhang X, Ning B, Guo J, Nie N, Liu B, Wu X. 2009. Down-regulated Mir-9 and Mir-433 in human gastric carcinoma. J Exp Clin Cancer Res 28: 82.
37. Mclemore TL, Hubbard WC, Litterst CL, Liu MC, Miller S, Mcmahon NA, Eggleston JC, Boyd MR. 1988. Profiles of prostaglandin biosynthesis in normal lung and tumor-tissue from lung-cancer patients. Cancer Res 48: 3140-3147.
38. Miura K, Bowman ED, Simon R, Peng AC, Robles AI, Jones RT, Katagiri T, He P, Mizukami H, Charboneau L, Kikuchi T, Liotta LA, Nakamura Y, Harris CC. 2002. Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res 62: 3244-3250.
39. Moog-Lutz C, Cave-Riant F, Guibal FC, Breau MA, Di Gioia Y, Couraud PO, Cayre YE, Bourdoulous S, Lutz PG. 2003. JAML, a novel protein with characteristics of a junctional adhesion molecule, is induced during differentiation of myeloid leukemia cells. Blood 102: 3371-3378.
40. Mostertz W, Stevenson M, Acharya C, Chan I, Walters K, Lamlertthon W, Barry W, Crawford J, Nevins J, Potti A. 2010. Age- and sex-specific genomic profiles in non-small cell lung cancer. JAMA 303: 535-543.
41. Nguyen DX, Bos PD, Massague J. 2009. Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284.
42. Nitta T, Takahama Y. 2007. The lymphocyte guard-Ians: Regulation of lymphocyte survival by IAN/GIMAP family proteins. Trends Immunol 28: 58-65.
43. Nuovo GJ, Elton TS, Nana-Sinkam P, Volinia S, Croce CM, Schmittgen TD. 2009. A methodology for the combined in situ analyses of the precursor and mature forms of micrornas and correlation with their putative targets. Nat Protoc 4: 107-115.
44. Osada H, Takahashi T. 2011. Let-7 And Mir-17-92: Small-sized major players in lung cancer development. Cancer Sci 102: 9-17.
45. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. 2010. Evaluation of microrna expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 70: 36-45.
46. Pochetuhen K, Luzina IG, Lockatell V, Choi J, Todd NW, Atamas SP. 2007. Complex regulation of pulmonary inflammation and fibrosis by CCL18. Am J Pathol 171: 428-437.
47. Raponi M, Dossey L, Jatkoe T, Wu XY, Chen GA, Fan HT, Beer DG. 2009. Microrna classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 69: 5776-5783.
48. Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A, Smyth GK. 2007. A comparison of background correction methods for two-colour microarrays. Bioinformatics 23: 2700-2707.
49. Rollinger-Holzinger I, Eibl B, Pauly M, Griesser U, Hentges F, Auer B, Pall G, Schratzberger P, Niederwieser D, Weiss EH, Zwierzina H. 2000. LST1: A gene with extensive alternative splicing and immunomodulatory function. J Immunol 164: 3169-176.
50. Schlingemann J, Thuerigen O, Ittrich C, Toedt G, Kramer H, Hahn M, Lichter P. 2005. effective transcriptome amplification for expression profiling on sense-oriented oligonucleotide microarrays. Nucleic Acids Res 33: E29.
51. Schutyser E, Richmond A, Van Damme J. 2005. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukocyte Biol 78: 14-26.
52. Schwender H, Krause A, Ickstadt K. 2006. Identifying interesting genes with siggenes. RNews 6: 45-50.
53. Shiao YM, Chang YH, Liu YM, Li JC, Su JS, Liu KJ, Liu YF, Lin MW, Tsai SF. 2008. Dysregulation of GIMAP genes in non-small cell lung cancer. Lung Cancer 62: 287-294.
54. Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA. 2010. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328: 749-752.
55. Smyth GK. 2004. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
56. Snijdewint FGM, Kalinski P, Wierenga EA, Bos JD, Kapsenberg ML. 1993. Prostaglandin-E(2) differentially modulates cytokine secretion profiles of human T-helper lymphocytes. J Immunol 150: 5321-5329.
57. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller PW, Portanova J, Lee JC, Dubinett SM. 2000. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 And IL-12 synthesis. J Immunol 164: 361-370.
58. Taniwaki M, Daigo Y, Ishikawa N, Takano A, Tsunoda T, Yasui W, Inai K, Kohno N, Nakamura Y. 2006. Gene expression profiles of small-cell lung cancers: Molecular signatures of lung cancer. Int J Oncol 29: 567-575.
59. Tusher VG, Tibshirani R, Chu G. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
60. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, Wernerus H, Bjorling L, Ponten F. 2010. Towards a knowledge-based human protein atlas. Nat Biotechnol 28: 1248-1250.
61. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: 0034.
62. Wang DZ, Dubois RN. 2010. Eicosanoids and cancer. Nat Rev Cancer 10: 181-193.
63. Wang DZ, Wang HB, Shi Q, Katkuri S, Walhi W, Desvergne B, Das SK, Dey SK, Dubois RN. 2004. Prostaglandin E-2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6: 285-295.
64. Wang Y, Lee ATC, Ma JZI, Wang JB, Ren JW, Yang YC, Tantoso E, Li KB, Ooi LLPJ, Tan P, Lee CGL. 2008. Profiling microrna expression in hepatocellular carcinoma reveals microrna-224 up-regulation and apoptosis inhibitor-5 as a microrna-224-specific target. J Biol Chem 283: 13205-13215.
65. Witherden DA, Verdino P, Rieder SE, Garijo O, Mills RE, Teyton L, Fischer WH, Wilson IA, Havran WL. 2010. The junctional adhesion molecule JAML is a costimulatory receptor for epithelial gamma delta T cell activation. Science 329: 1205-1210.
66. Wolf MJ, Seleznik GM, Zeller N, Heikenwalder M. 2010. The unexpected role of lymphotoxin beta receptor signaling in carcinogenesis: From lymphoid tissue formation to liver and prostate cancer development. Oncogene 29: 5006-5018.
67. Wu H. 2010. Tumor-microenvironment interactions studied by zonal transcriptional profiling of squamous cell lung carcinoma. Inaugural Dissertation. Heidelberg, Germany: University Of Heidelberg, pp. 1-136.
68. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Colin GA, Liu CG, Croce CM, Harris CC. 2006. Unique microrna molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198.
69. Yoshimoto A, Kasahara K, Kawashima A, Fujimura M, Nakao S. 2005. Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: A comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases. Oncol Rep 13: 1049-1057.
70. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, Su TJ, Chiang CC, Li HN, Hong QS, Su HY, Chen CC, Chen WJ, Liu CC, Chan WK, Chen WJ, Li KC, Chen JJW, Yang PC. 2008. Microrna signature predicts survival and relapse in lung cancer. Cancer Cell 13: 48-57.
71. Zeddou M, Greimers R, De Valensart N, Nayjib B, Tasken K, Boniver J, Moutschen M, Rahmouni S. 2005. Prostaglandin E-2 induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8(+) T lymphocytes by a camp-dependent protein kinase A type I pathway. Biochem Pharmacol 70: 714-724.
72. Zhang YL, Liu QY, Zhang MG, Yu YZ, Liu X, Cao XT. 2009. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE(2). J Immunol 182: 3801-3808.
73. Zhang X, Zhu W, Zhang J, Huo S, Zhou L, Gu Z, Zhang M. 2010. Microrna-650 targets ING4 to promote gastric cancer tumorigenicity. Biochem Biophys Res Commun 395: 275-280.
74. Zhu CQ, Pintilie M, John T, Strumpf D, Shepherd FA, Der SD, Jurisica I, Tsao MS. 2009. Understanding prognostic gene expression signatures in lung cancer. Clinical Lung Cancer 10: 331-340.